EDWARDS LIFESCIENCES CORP

Edwards Lifesciences shares dipped 1.13% to $89.07, staying above its 200‑day average. With a $51.3B market cap and a strong product line, the company remains a resilient player in cardiovascular technology.

Edwards Lifesciences gains 1.91% as investors applaud its growing heart‑valve tech and robust market cap of $51B, promising solid upside.

Edwards Lifesciences shares rise 0.12% at $88.40, amid steady market cap of $50.9B and strong peer comparison.

Edwards Lifesciences: modest Q1 earnings, production hiccups, but steady cash flow and a strong R&D pipeline position it for sustained growth in heart‑valve markets.

Edwards Lifesciences (EW) posts a modest 0.72% gain at $88.22, trading above its 200‑day MA while maintaining a $49.9B market cap—solid momentum for a mature heart‑care stock.